RNA interference (RNAi) is a natural cellular regulatory process that inhibits gene expression by transcriptional, post-transcriptional and translational mechanisms. Synthetic approaches that emulate this process (small interfering RNA (siRNA), short hairpin RNA (shRNA)) have been shown to be similarly effective in this regard. We developed a novel 'bifunctional' RNAi strategy, which further optimizes target gene knockdown outcome. A bifunctional construct (bi-sh-STMN1) was generated against Stathmin1, a critical tubulin modulator that is overexpressed in human cancers. The bifunctional construct is postulated to concurrently repress the translation of the target mRNA (cleavage-independent, mRNA sequestration and degradation) and degrade (through RNase H-like cleavage) post-transcriptional mRNA through cleavage-dependent activities. Bi-sh-STMN1 showed enhanced potency and durability in parallel comparisons with conventional shRNA and siRNAs targeting the same sequence. Enhanced STMN1 protein knockdown by bi-sh-STMN1 was accompanied by target site cleavage at the mRNA level showed by the rapid amplification of complementary DNA ends (RACE) assay. Bi-sh-STMN1 also showed knockdown kinetics at the mRNA level consistent with its multieffector silencing mechanisms. The bifunctional shRNA is a highly effective and advantageous approach mediating RNAi at concentrations significantly lower than conventional shRNA or siRNA. These results support further evaluations.
Introduction
RNA interference (RNAi) is a natural cellular regulatory process capable of inhibiting transcriptional, post-transcriptional and translational mechanisms thereby modulating gene expression. [1] [2] [3] [4] RNAi technology is commonly used in reverse genetics approaches to study gene function and to show targets of therapeutic potential in cancer. [5] [6] [7] Several synthetic methods of silencing gene expression integral to disease phenotype have been developed. 8, 9 Short hairpin RNA (shRNA) transcribed from an expression vector intrinsically differs from synthetic double-stranded small interfering RNA (siR-NA) with respect to intracellular trafficking and nucleotide preference 10 and can result in enhanced gene knockdown effects. Recently, the process of RNAi by endogenously expressed hairpin RNAs, known as microRNAs (miRNAs), has been shown in mammalian cells. 11 By integrating an siRNA motif in the context of the wellknown miR30-scaffold, shRNA expressed from constructs of defined specificity against a target gene can be processed through the endogenous miRNA biogenesis pathway. 12 Using a miR30-scaffold, we developed a novel 'bifunctional' (bi) RNAi strategy. We postulate that a bifunctional construct that concurrently induces translational repression (cleavage-independent mRNA sequestration and degradation) and cleavage-dependent post-transcriptional mRNA degradation can achieve more effective silencing in comparison with siRNA or conventional single-functional shRNA targeted to the same sequence. The bifunctional construct bi-sh-STMN1 is directed against Stathmin1 (STMN1), a gene target candidate that is overexpressed in human cancer lines and was shown by us to be differentially overexpressed in cancer patients, based on mRNA and protein couplet signals in tumor/ normal tissue specimen analysis. 13 STMN1 is critically involved in mitotic spindle formation. 14, 15 Previously, studies have shown that STMN1 knockdown by conventional siRNA resulted in G 2 /M cell cycle arrest, inhibition of clonogenicity and markedly increased apoptosis. [15] [16] [17] STMN1 knockdown also produced an additive to synergistic interaction with chemotherapeutic agents such as the taxanes. [18] [19] [20] The bi-sh-STMN1 incorporates two stem-loop structures in an expression construct promoting both cleavagedependent and cleavage-independent RNA-induced silencing complex (RISC) assemblies thereby generating RISC-associated mature effector small RNAs with multiple independent gene silencing activities. On the basis of the observation that miRNAs are associated with both non-nucleolytic (Ago1, 3, 4) and nucleolytic Ago2-containing RISC and siRNAs with the nucleolytic Ago2, the novel bifunctional strategy specifically promotes the loading of miRNA-like effector molecules onto the cleavage-independent RISC as well as the accumulation of siRNA effector molecules by the cleavagedependent (Ago2 containing) RISC. 21 The bifunctional design thermodynamically accommodates passenger strand departure through cleavage-dependent and cleavageindependent processes so the functionality of the effectors is, thereby, set by programmed passenger strand guided RISC loading rather than being dependent on the Ago protein distribution in the target cell. Insofar as the bifunctional construct uses a natural process (that is, miRNA biogenesis), the host RNA polymerase II complex can be used to allow expression of multiple bifunctional shRNAs targeting multiple key overexpressed genes in tumor with a single primary transcript transcribing from a RNA pol II promoter 22, 23 structurally analogous to the miR17-92 cluster on chromosome 13 with 6 miRNAs expressed in a poly-cistronic manner. 24 In this proof of principle study, we showed effective target knockdown and significant dose advantage in vitro in tumor cell killing when compared with conventional shRNA and siRNA targeting the STMN1 target gene.
Materials and methods
Materials and cell lines siRNAs were purchased from Ambion (Austin, TX), DNA oligos were purchased from Integrated DNA Technologies (Coralville, IA), restriction enzymes were obtained from New England BioLabs (Ipswich, MA). DNA sequencing was carried out by SeqWright (Houston, TX). HCT-116 (ATCC# CCL-247), MDA-MB-231, and SK-MEL-28 cell lines were obtained from ATCC (Manassas, VA). Cells were cultured under the condition recommended by ATCC. Early passage cells were used for experiments.
Construction of STMN1 uni-functional shRNA (pGBI-1, pGBI-3) and bifunctional shRNA (bi-sh-STMN1, or pGBI-2) The bi-sh-STMN1 consists of two stem-loop structures with miR-30 backbone. The first stem-loop structure has a complete complementary guide strand and passenger strand, while the second stem-loop structure has two base pair mismatches at positions 11 and 12 of the passenger strand. The sequences for both stem-loop structures are as follows:
Complete matching strands (5 0 -AAGGATCCTGCTGTT GACAGTGAGCGCGGCACAAATGGCTGCCAAATAG TGAAGCCACAGATGTATTTGGCAGCCATTTGTG CCTTGCCTACTGCCTCGGAAGCTTTG-3 0 ); Strands with mismatches (5 0 -AAGGATCCTGCTGTT GACAGTGAGCGCGGCACAAATGATTGCCAAATA GTGAAGCCACAGATGTATTTGGCAGCCATTTGT GCCTTGCCTACTGCCTCGGAAGCTTTG-3 0 ), where underlined are nucleotide differences between complete match and mismatched strands.
Two stem-loop structures were synthesized independently with two pieces of synthetic oligonucleotides each with overlapping sequences and fill-in reaction with T4 DNA polymerase to complete the double-stranded DNA for restriction digest and insertion into the plasmids. Each stem-loop structure was individually inserted into pSilencer vector between BamHI and HindIII sites (Ambion). To join the two shRNA expression units, the HindIII site at the 3 0 end of the stem-loop structure with complete matching strands expression unit was changed into a BglII site (5 0 -TGAGATCTCCGAGGCAGTAGGCA-3 0 ) and the BamHI site at the 5 0 end of the mismatching strands expression unit was then joined to the 3 0 end of strands with complete matching expression unit through the BglII site to establish the bifunctional expression unit.
To move the shRNA expression units from pSilencer into pUMVC3 vector, PCR primer was used to change the BamHI sites to SalI site (BamHI to SalI primer, 5
0 -AA GTCGACTGCTGTTGACAGTG-3 0 ), PCR amplification with F seq primer (5 0 -AGGCGATTAAGTTGGG TA-3 0 ), and the resulting PCR fragments were digested with SalI and NotI and inserted into the SalI and NotI sites of pUMVC3.
Sequence confirmation and vector production
The insert sequences were confirmed by sequencing from both directions with primers flanking the insert. The sequencing was performed by SeqWright.
For small-scale production, vector DNA were purified from Escherichia coli by EndoFree Plasmid Maxi kit (Qiagen, Valencia, CA). Purified plasmid DNA was quantified with Nanodrop ND-100 spectrophotometer (NanoDrop, Willmington, DE). Large-scale production of the Good Laboratory Practice quality plasmid DNA were contract produced by Aldevron (Fargo, ND). The inserts of Good Laboratory Practice-produced plasmids were also sequence confirmed.
Transfection of cell lines with siRNA or shRNA Reverse transfection of cell lines was carried out with siPort NeoFX (Ambion) for siRNA or siPort Amine (Ambion) for shRNA by following the protocol recommended by the manufacturer. Transfection efficiency was routinely monitored by a green fluorescent protein expression vector and percentage green fluorescent protein-positive cells scored by flow cytometry analysis. Briefly, 1 h before transfection, healthy growing adherent cells were trypsinized and re-suspended in normal growth medium at 1 Â 10 5 cells ml -1 . siPORT NeoFX (or Amine) (5 ml per well) was diluted into a predetermined volume of Opti-MEM 1 medium (100 ml per well) for each six-well plate used and incubated for 10 min at room temperature. siRNA (plasmid DNA) was diluted into Opti-MEM 1 medium for a final concentration of 10-30 nM (1-3 mg ml -1 for shRNA), as required, in 100 ml per well volume of OptiMEM1. The diluted siPORT NeoFX (or Amine) and the diluted RNA (or plasmid DNA) were combined and incubated 10 min at room temperature. The transfection complexes were then dispensed into the empty six-well plates (200 ml per well). The trypsinized cells prepared earlier were gently mixed and 2.3 ml of the 1 Â 10 5 cells ml -1 were overlayed into each well of the six-well plates, which were gently rocked back and forth to evenly distribute the complexes. The final volume of transfection was 2.5 ml per well. Incubation was performed at 37 1C checking after 8 h for any cytotoxicity. If Cytotoxicity was noticed, the media was replaced with fresh media. Fresh media was replaced after 24 h. The cells were assayed at 24, 48 h and 4 days after transfection for protein knockdown by Western, flow-cytometry or reverse transcription-polymerase chain reaction (RT-PCR). Transfections were also carried out with Transfectamine 2000 (Invitrogen, Carlsbad, CA) with the protocol recommended by the manufacturer.
RNA isolation
Total cellular RNA isolation was accomplished with RNeazy mini-kit (Qiagen) or with mirVana miRNA isolation kit (Ambion) by following manufacturer's recommendations. 0 PCR primer and STMN1 genespecific primer 2).
Stem-loop RT-PCR

Quantitative RT-PCR
In all, 1 mg of isolated total cellular RNA was converted to cDNA using oligo dT primer in a 20 ml reaction with Superscript III First-Strand Synthesis System (Invitrogen). The synthesized cDNA was diluted 100-fold and 5 ml of diluted cDNA was amplified in a 25 ml QPCR reaction with SyberGreen in a iQ5 Multicolor Real-Time PCR Detection System (Bio-Rad, Hercules, CA). A pair of PCR primers was designed to span the predicted cleavage site of STMN1 so as to measure pGBI-2-mediated knockdown of STMN1 mRNA (forward primer: 5 0 -TG GCAGAAGAGAAACTGACCCACA-3 0 ; reverse primer: 5 0 -TCGTCAGCAGGGTCTTTGGATTCT-3 0 ). Glyceraldehyde 3-phosphate dehydrogenase (forward primer: 5 0 -CGACCACTTTGTCAAGCTCA-3 0 ; reverse primer: 5 0 -CGACCACTTTGTCAAGCTCA-3 0 ) was used as internal control to normalize STMN1 gene expression with DDCt method to analyze the relative STMN1 gene expression. All samples treated with either pGBI-1, pGBI-2 or pGBI-3 was compared with media-control samples and the changes of STMN1 expression were presented as percentage of media-control.
Flow cytometry analysis
Transfected or untransfected cells were washed, trypsinized and collected. A small aliquot is removed for a cell count. In all, 1 Â 10 6 cells were then pelleted and resuspended in 500 ml of Cyto Fix and Perm solution (BD Biosciences, Rockville, MD) for 10 min at room temperature. After 10 min, cells were washed with 1 ml of PermWash. After wash, the pellet is resuspended in 300 ml of PermWash buffer and divided into three tubes of 100 ml each. One tube was for unstained control, second tube was for isotype control. Third tube was for rabbit antihuman STMN1 (purified antibody) followed by secondary goat anti-rabbit IgG (phycoerythrin), or rabbit anti-human b-actin followed by secondary goat antirabbit IgG (phycoerythrin). In total, 10 ml of primary antibody was used for each sample and incubated at 4 1C for 30 min, followed by a rinse with 1 ml of PermWash Enhanced target gene knockdown by a bifunctional shRNA DD Rao et al buffer, incubated with 10 ml per sample of the phycoerythrin-labeled secondary antibody for 10 min at 4 1C in the dark. After tagging the cells with secondary antibody, the cells are washed 2 Â with 1.0 ml of PermWash. After the last wash, the cells were resuspended in Staining Buffer and read using the fluorescence-activated cell sorting Caliber (BD Biosciences) and data analyzed using CellQuest Pro software (BD Biosciences) to quantify the STMN1 or b-actin stained cells.
Western immunoblotting
Cells were lysed with lysis buffer CellLytic-M and scraped off the surface of the culture dish incubate at room temperature for 30 min on a slow shaker, and briefly centrifuged. A small aliquot for protein concentration estimation by Coomassie Bradford Plus Assay was taken with bovine serum albumin as standard. The SoftMaxPro software (Molecular Devices, Sunnyvale, CA) was used to calculate the values and plot the standard curve. Equal amounts of protein were separated on a pre-assembled gel (usually 5-20 mg) 15% polyacrylamide gel electrophoresis using Mini-Protein II Cell system (Bio-Rad). After electrophoresis, the separated proteins were electrotransferred on to a polyvinylidene fluoride membrane with standard condition. Transferred membranes were first blocked with blocking buffer containing 5% non-fat dried milk in Dulbecco's phosphate buffered saline overnight at 4 1C. After two changes of wash buffer, proteins were tagged first with determined dilution of primary antibody and then horseradish peroxidaseconjugated secondary antibody. Chemiluminescent detection was carried out by ECL plus western blotting detection reagents with G:BOX Chemi XT16 automated chemiluminescence image analyzer (Syngene, Frederick, MD). Membranes can be stripped and re-probed with a different antibody or house keeping protein such as b-actin.
Viable cell count
The cell numbers of transfected and untransfected control were determined by EasyCount System (Immunicon, Huntingdon Valley, PA). The EasyCount System, together with the EasyCount ViaSure Kit, provides automated counting of live and dead nucleated cells. Briefly, the tissue culture cells were trypsinized to prepare cell suspensions in growth medium. In total, 25 ml of cell suspensions and 25 ml of fluorescent staining reagent were gently mixed. In all, 10 ml of the mixture were loaded to the EasyCount slide and the total cells and the viable cells were measured by EasyCount device.
Statistical analysis
All data analyses were performed using SPSS 13.0 (SPSS Inc., Chicago, IL). One-way analysis of variance was performed to see if there were any differences in cell survival between low, medium and high doses of bi-sh-STMN1 and untreated cells for cell cycle analysis. Post hoc comparisons were made using the Tukey's Honestly Significant Difference test to identify wherein mean cell survival differences occurred between the varying treated and untreated cells. Similar analysis was applied to siRNA, shRNA and bi shRNA comparisons. A repeated-measures analysis of variance, followed by a Tukey's Honestly Significant Difference post hoc test, was performed to look for differences in the kinetics of cell survival at various doses of siRNA, shRNA and bi shRNA over time after transfection.
Results
Vector design and cell line selection for in vitro studies
The design of the bifunctional expression vector incorporated both cleavage-dependent and cleavage-independent structural components ( Figure 1a ) designed to promote differential RISC assembly and, consequently, produce Ago 2 and non-nucleolytic Ago protein effectors directed against the same target sequence on STMN1 mRNA. 25 To the point, translational repression by siRNAs with full complementarity to reporter mRNA can occur independent of Ago 2. 25 The cleavage-dependent component requires complete matching sequences of the passenger and guide strands for optimal activity. After processing by the RNase III enzyme Dicer, the double-stranded RNA is bound by the RISC loading complex (RISC loading complex incorporating Dicer, TRBP and AGO2) and the passenger strand is cleaved by the RNase H-like activity of Ago 2 (encoded by its P-element induced wimpy testis in Drosophila domain) liberating the guide strand which, as a component of RISC binds to and cleaves complementary target mRNA (cleavage-dependent process). In addition, our bifunctional vector incorporates a cleavage-independent component, which contains mismatches between the passenger and guide strands at the ostensible cleavage site resulting in a lower thermodynamic stability that promotes the dissociation of the passenger strand through a cleavage-independent process. 26, 27 This component will in effect be loaded onto non-nucleolytic Ago protein RISCs and function through mRNA sequestration and translation repression. 11 The expression unit for the bifunctional shRNA to Stathmin1 (bi-sh-STMN1) is inserted between the SalI and NotI sites of mammalian expression vector pUMVC3 ( Figure 1b) and is driven from an enhanced (pol II) cytomegalovirus promoter. 28 It contains two stem-loop structures in a previously described miR-30 backbone, 12 one with complete matching passenger and guide strands (cleavage-dependent), and the other with 2-bp mismatches between passenger and guide strands (cleavage-independent). The GC to AU switches are at positions 11 and 12 of the passenger strand, which create mismatches at the central location similar to most miRNAs 26 (predicted secondary structure shown on Figure 1c) .
The STMN1 mRNA target site we selected was based on maximal knockdown efficacy as determined by comparison of several commercially available siRNA STMN1 s. The selected target site was also screened with the Basic Local Alignment Search Tool local alignment program to limit the potential matches or 'seed sequence' matches with other human transcripts. For comparative purposes and for 
consistency, the selected STMN1 mRNA target site was used for siRNA and for all shRNA expression constructs throughout this study. To test whether the STMN1 expression could be effectively knocked down with each of the separate components of the bi-sh-STMN1 construct, CCL-247 cells were transfected with either 1, 2 or 3 mg ml -1 of the pGBI-1 (cleavage-dependent component) or of the pGBI-3 (cleavage-independent component) plasmid. Both effectors at all three doses knocked down STMN1 protein expression at 48 h after transfection (data not shown).
For in vitro study, we chose to show activity in cell lines overexpressive of STMN1 protein. As such, we compared a battery of cell lines and found a wide variation of STMN1 protein expression, which could be grouped into low, medium and high STMN1-expressing cells by normalizing to STMN1 expression in peripheral blood cells (with lowest STMN1 expression); low STMN1-expressing cells are less than fivefold elevated from peripheral blood cells, medium-expressing cells are o20-fold elevated, while high-expressing cells are 420-fold elevated in comparative expression (data not shown). Two medium STMN1-expressing cell lines, colon cancer cell line CCL-247 and melanoma cell line SK-MEL-28 and a high STMN1-expressing cell line, breast cancer cell line MDA-MB-231 were selected for our in vitro studies.
Detection of product effector molecules
Insofar as the bifunctional construct (bi-sh-STMN1; pGBI-2) consists of two stem-loop structures of similar sequence in tandem (Figure 1c) , we first sought to confirm the effective synthesis and maturation of both types of effector molecules in the bi-sh-STMN1-transfected cells. Using an adapted highly sensitive and specific stemloop RT-PCR method that was developed to detect 28 we confirmed that the guide strands derived from the bi-sh-STMN1 were as predicted (Figure 2a (Figure 2a, lane 3) .
Using primers specific either for the matched or mismatched passenger strands, we further confirmed that both matched and mismatched passenger strands were present in the bi-sh-STMN1-transfected cells (Figure 2b , lane 4 for matched passenger strand, lane 9 for mismatched passenger strand), whereas only the fully matching passenger strand was detected from the siRNA STMN1 -transfected cells (Figure 2b , lane 5). No RT-PCR product was detected from untransfected cells or cells transfected with scrambled shRNA. These findings support our premise that mature, cleavage-dependent and -independent effectors were produced after bi-sh-STMN1 transfection.
Validation of target site cleavage
The cleavage-dependent component of the bi-sh-STMN1 construct should be able to induce STMN1 target site cleavage. The 5 0 RACE method was used to validate target site cleavage as predicted from the cleavagedependent siRNA component of bi-sh-STMN1. 29 We designed gene-specific primers both for RT and for PCR. For PCR, we also used the gene-specific nested primer strategy to reduce any nonspecific background. The RACE PCR product with predicted size was detected in cells transfected with either bi-sh-STMN1 or siRNA STMN1 ( Figure 3 , lanes 4 or 5, respectively, red arrow), and was confirmed by DNA sequencing to represent a STMN1 mRNA fragment after cleavage between nucleotide position 10 and 11 of the sense strand.
STMN1 protein knockdown
To show the specificity of target protein knockdown, after transfection with bi-sh-STMN1, CCL-247 cells were tagged with STMN1-specific antibody for flow cytometry analysis. At 48 h after transfection, flow cytometry analysis showed 93% reduction in STMN1 protein expression (shift in fluorescent intensity, Figure 4 , upper panels) as compared with untreated control. By contrast, treatment with the scramble control did not result in STMN1 reduction. b-Actin expression was not changed by bi-sh-STMN1 treatment (Figure 4 , lower panels).
Comparative STMN1 protein knockdown and mRNA knockdown kinetics Comparative STMN1 protein expression was assessed by western immunoblot. At 48 h after transfection of SK-MEL-28 cells, the bi-sh-STMN1 (pGBI-2) is the most . Total cellular RNA was reversetranscribed with passenger strand-specific stem-loop RT primer for cDNA synthesis. Two primer sets were used to differentiate shRNA with or without mismatches. cDNA was amplified with passenger strand-specific primers either for the complete match passenger strand (lanes 2-6) or for passenger strand with mismatches (lanes 7-11) and stem-loop-specific PCR primer sets. PCR amplified products were run onto a 4% agarose gel and stained with ethidium bromide and visualized under ultraviolet (UV) light. The amplified PCR products were sequence confirmed. We also evaluated the mRNA knockdown kinetics of the composite bifunctional construct (pGBI-2) compared with constructs comprised each of the individual components using SK-MEL-28 cells. Figure 5b illustrates the comparative target mRNA knockdown kinetics over the 72 h after exposure to pGBI-1, -3 and bi-sh-STMN1 (pBGI-2) as determined by quantitative RT-PCR. The quantitative RT-PCR primers were designed to flank the target site for the most effective detection of target site cleavage-mediated STMN1 mRNA knockdown. pGBI-1 (cleavage-dependent mRNA degradation only) induced STMN1 mRNA knockdown was evident at 24 h, peaking at 48 h. By comparison, with pGBI-3 treatment (through translational inhibition and/or sequestration in the p-body with or without subsequent mRNA deadenylation, decapping and degradation, in spite of the same target sequence) 30, 31 STMN1 mRNA was more abundant at 24 and 48 h compared with the untreated cells and started to decline only at 72 h after transfection. The STMN1 mRNA knockdown response to the bi-sh-STMN1 (pGBI-2) was evident at 48 h and continued to increase at 72 h. We could not ascertain changes at later time 
Cancer cell growth inhibition
There was a dose-response pattern of CCL-247 cell survival after treatment with all three constructs; the bi-sh-STMN1 with an IC 50 of 1.81 Â 10 À13 M at 24 h, pGBI-1 with an IC 50 of 3.61 Â 10 À13 M and pGBI-3 with an IC 50 of 7.22 Â 10 À13 M (Figure 6a ). Additional cell survival results with bi-sh-STMN1 were shown with MDA-MB-231 and SK-MEL-28 cells; the dose requirements for cancer cell growth inhibition were observed to differ between the cell lines (data not shown). The dose-response data suggested an advantage of the bi-sh-STMN1 over pGBI-1 and pGBI-3 at the low-dose range (10
À13
-10 À14 M range, Figure 6a ). We next examined the bi-sh-STMN1 construct's effect on cancer cell growth inhibition over 72 h as compared with each of it's individual components (pGBI-1 and pGBI-3) at three different doses that are lower than the IC 50 for the bifunctional with 3.61 Â 10 À13 M as the highest dose and two additional lower doses (9.02 Â 10 À13 M), all three constructs inhibited cancer cell growth equally (data not shown). At the 9.02 Â 10 À14 M, all three constructs were observed to significantly inhibit CCL-247 growth for the 3-day period when compared with the no treatment control (Figure 6b ), but the bi-sh-STMN1 construct was able to sustain growth inhibition more effectively through day 3 when compared with the single component construct (pGBI-2 vs pGBI-1, P ¼ 0.002; pGBI-2 vs pGBI-3, P ¼ 0.003). Even at the lowest dose (2.26 Â 10 À14 M), bi-sh-STMN1 showed a significant difference in growth inhibition compared with both the individual cleavage-dependent (pGBI-1) and -independent (pGBI-3) constructs (bi-sh-STMN1 vs pGBI-1, Po0.001, bi-sh-STMN1 vs pGBI-3, Po0.001) (Figure 6c ).
Compare bi-sh-STMN1 with its siRNA counterpart We next compared the performance of bi-sh-STMN1 with siRNA STMN1 . CCL-247 cell growth inhibition was monitored over a wide range of concentrations of siRNA STMN1 and compared with the dose response of bi-sh-STMN1. The bi-sh-STMN1 resulted in significantly greater tumor cell kill (lower percent survival) than the siRNA (P ¼ 0.004) (Figure 7 ). Using the 5 0 RACE method the target-specific cleavage product was readily detected at essentially all siRNA concentrations, while the cleavage product was only detected at the higher dose of bi-sh-STMN1 (Figure 7) , thereby supporting an additional non-cleavage-dependent mechanism of action consistent with bi-sh-STMN1 design.
Discussion
The miR-30 backbone used in our design is reported to undergo a biogenesis process similar to endogenous miRNA. 12 The primary transcripts of endogenous miRNAs are synthesized from genomic DNA in the nucleus as long RNA strands with hairpin structures, which are further processed to mature 21-23 bp doublestranded miRNA through a series of RNase III enzyme digests. The maturation process involves at least two RNase III enzyme complexes; first, the Drosha/DGCR8 microprocessor complex produces the pre-miRNA hairpin structure which, after nuclear export through Exportin 5, is incorporated into the RISC loading complex in which the second enzyme, Dicer, excises the loop producing the mature miRNA, 32 which is the effector molecule that is loaded onto RISC for RNAi. 33 As previously noted, the differential distribution of nonnucleolytic (Ago1, 3, 4) and nucleolytic Ago2 (mAgo1, 3, 4/Ago2) in the cleavage-independent RISC (miRNA-like) and the specific accumulation of Ago2 protein in the cleavage-dependent RISC (siRNA) 21 determine the functionality of the effectors. To determine if our designed bi-sh-STMN1 is accurately processing and successfully producing both types of the mature effector molecules (double-stranded RNA with 3 0 overhangs and complete matching strands and double-stranded RNA with 3 0 overhangs and specified mismatches), we adapted the RT-PCR method developed for miRNA 34 to detect Results confirmed the presence of the predicted mature cleavage-dependent/cleavage-independent components. Moreover, we confirmed that both matched and mismatched passenger strands were synthesized from the bi-sh-STMN1 cells whereas only the fully matching strand was detected for the siRNA STMN1 -transfected cells. It appeared that the mismatched passenger strand was present in higher steady-state quantities than the matched passenger strand, which is consistent with cleavage of the fully matching passenger strand by Ago 2. However, insofar as the analysis of the RT-PCR product by agarose gel electrophoresis is only semi-quantitative, quantitative studies with TaqMan probes will be required to further assess this finding. To additionally support the hypothesized mechanism of the bi-sh-STMN1, we used the (Figure 5a , 44% for bi-sh-STMN1, 29% for pGBI-1 and 11% for pGBI-3) presumably because of differences in transfection efficacy and cell growth rate. However, in comparison with its individual cleavage-dependent and cleavage-independent components, the bi-sh-STMN1 produced the most efficient protein knockdown. Although bi-sh-STMN1 is the most efficient in protein knockdown, it is comparatively less efficient in target mRNA knockdown than pGBI-1 (cleavage-dependent component only) at 48 h as measured by quantitative RT-PCR. This observation is consistent with our suggested hypothesis that the bi-sh-STMN1 is, in effect, working through multiple RNAi pathways. During the initial 48 h of kinetics testing (Figure 5b) , the bi-sh-STMN1 results in both mRNA degradation and sequestration, thus the bi-sh-STMN1 seems to be less effective than pGBI-1 in knockdown at the mRNA level. However, presumably, for the bi-sh-STMN1 (with both cleavage-dependent and -independent motifs), both mRNA cleavage (RNase H-like mechanism) and mRNA sequestration into the p-body initially occur followed at a later time by deadenylation-mediated decapping and mRNA degradation within the p-body, thereby appearing to be less efficient at target mRNA knockdown than pGBI-1 during the first 48 h, but producing additive STMN1 mRNA cleavage and degradation at a later time reflecting the temporal pattern of pGBI-3). Conversely, at the protein level (Figure 5a ) as well as at the functional level (Figure 6b and c) , the bifunctional seems to be more effective than either pGBI-1 or -3. Specifically, although the cleavage-dependent construct results in a 38% mRNA knockdown vs 15% by the bifunctional within the first 48 h after transfection, the bifunctional construct contemporaneously results in a 44% protein knockdown vs 29% by the cleavagedependent construct. Given that complementary 3 0 -UTR specific miRNA mimics can effect mRNA degradation, 35 which could suggest that enhanced bifunctional efficacy is simply because of a siRNA dosing effect, the difference in pGBI-1-and pGBI-3-mediated mRNA knockdown kinetics show the differing mechanisms of action of the individual bifunctional components, which derives from differential Ago-containing RISC loading. We will further confirm the differential RISC loading using immunoprecipitation of each Ago protein-containing RISC at a later date. 21, 36 Insofar as the same concentrations of plasmids used for all three constructs in this set of experiments, are expected to lodge the same number of plasmid copies in transfected cells and, therefore, the same number of primary transcripts under the same transfection conditions, the number of effector molecules are the same for each separate construct set. Thus, these data support the additive, if not synergistic, effect of the bifunctional construct.
Having evaluated an alternative effector mechanism and shown the functional efficacy of the bi-sh-STMN1 vector, we further examined anticancer activity in vitro and successfully showed effective cell kill in several cancer cell lines of different cancer types. Studies are underway to correlate STMN1 expression level in different cell types in relation to effective dose requirement.
We also compared bi-sh-STMN1 with siRNA directed against the same STMN1 target site. The bi-sh-STMN1 achieved an IC 50 at 5 logs lower molar concentration than siRNA STMN1 . There is evidence of functional siRNA nuclear activity early after cell entry 37, 38 and with subsequent nuclear exclusion of siRNA mediated by exportin 5 has been shown in human cells. 37, 38 However, within 4 h after transfection, siRNA has completely relocated to the cytoplasm although at 48 h only 1% of initial delivered siRNA is available to mediate activity. 39 There are several strategies to modify siRNA to improve intracellular stability. 40 However, after vector-based Enhanced target gene knockdown by a bifunctional shRNA DD Rao et al DNA achieves stability within the nucleus 41 and steadily produces shRNA through its pol II promoter, which allows for spatial and temporal control, thereby providing a continuous expression of inhibitory effectors with a prolonged functional half-life. In addition, the bifunctional strategy is postulated to act multifunctionally by cleaving target mRNA, effectively reducing target mRNA concentration, inhibiting target mRNA translation, and sequestering the target mRNA from the translation machinery (p-body) with the potential for delayed degradation, thereby providing an efficient and sustained RNAi mode. Our results are consistent with this hypothesis. These factors could account for the more than 5-log molar difference in applied dose concentration observed between bi-sh-STMN1 and siRNA STMN1 to achieve similar tumor cell growth inhibition in vitro.
In conclusion, the bi-sh-STMN1 is a novel agent based on the RNAi strategy of purposively targeting gene expression for silencing through both mRNA cleavage and translational repression/p-body sequestration at a significantly lower dose than conventional siRNA and shRNA so as to achieve the same anticancer effectiveness with less potential for exportin 5 and RISC saturation as well as reducing the risk of off-target effects. In addition to structuring a more potent effector, this construct also allows for spatial and temporal control with the use of a single promoter for efficient multiplexing, with an ultimate aim of achieving simultaneous knockdown of multiple key targets in the same cell. Construction of targeting lipoplexes for systemic delivery and further in vivo safety, target specific knockdown assessment and assessment of target-dependent anticancer activity are justified.
